189 related articles for article (PubMed ID: 14998428)
1. Trends in accessibility to medicines for children in New Zealand: 1998-2002.
Chui J; Tordoff J; Kennedy J; Reith D
Br J Clin Pharmacol; 2004 Mar; 57(3):322-7. PubMed ID: 14998428
[TBL] [Abstract][Full Text] [Related]
2. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
Chui J; Tordoff J; Reith D
Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
[TBL] [Abstract][Full Text] [Related]
3. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.
Balakrishnan K; Tordoff J; Norris P; Reith D
Br J Clin Pharmacol; 2007 Jan; 63(1):85-91. PubMed ID: 16869822
[TBL] [Abstract][Full Text] [Related]
4. The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand.
Aaltonen K; Ragupathy R; Tordoff J; Reith D; Norris P
Value Health; 2010; 13(1):148-56. PubMed ID: 19744294
[TBL] [Abstract][Full Text] [Related]
5. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
6. Access to children's medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007.
Ragupathy R; Tordoff J; Norris P; Reith D
Pharm World Sci; 2010 Jun; 32(3):386-93. PubMed ID: 20354788
[TBL] [Abstract][Full Text] [Related]
7. Effect of the pediatric exclusivity provision on children's access to medicines.
Grieve J; Tordoff J; Reith D; Norris P
Br J Clin Pharmacol; 2005 Jun; 59(6):730-5. PubMed ID: 15948940
[TBL] [Abstract][Full Text] [Related]
8. Access to prescribing information for paediatric medicines in the USA: post-modernization.
Young L; Lawes F; Tordoff J; Norris P; Reith D
Br J Clin Pharmacol; 2009 Mar; 67(3):341-6. PubMed ID: 19220278
[TBL] [Abstract][Full Text] [Related]
9. Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002.
Balakrishnan K; Grieve J; Tordoff J; Norris P; Reith D
J Clin Pharmacol; 2006 Sep; 46(9):1038-43. PubMed ID: 16920899
[TBL] [Abstract][Full Text] [Related]
10. Availability of pediatric-evaluated formulations in Serbia.
Božić B; Stupar S; Stupar D; Babić U; Bajčetić M
Indian J Pharmacol; 2017; 49(2):189-193. PubMed ID: 28706333
[TBL] [Abstract][Full Text] [Related]
11. Off-label and unlicensed utilisation of medicines in a French paediatric hospital.
Joret-Descout P; Prot-Labarthe S; Brion F; Bataille J; Hartmann JF; Bourdon O
Int J Clin Pharm; 2015 Dec; 37(6):1222-7. PubMed ID: 26394784
[TBL] [Abstract][Full Text] [Related]
12. The availability and age-appropriateness of medicines authorized for children in The Netherlands.
van Riet-Nales DA; de Jager KE; Schobben AF; Egberts TC; Rademaker CM
Br J Clin Pharmacol; 2011 Sep; 72(3):465-73. PubMed ID: 21477143
[TBL] [Abstract][Full Text] [Related]
13. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
14. The use of ethanol in paediatric formulations in New Zealand.
Svirskis D; Toh M; Ram S
Eur J Pediatr; 2013 Jul; 172(7):919-26. PubMed ID: 23440480
[TBL] [Abstract][Full Text] [Related]
15. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.
Neubert A; Dormann H; Weiss J; Egger T; Criegee-Rieck M; Rascher W; Brune K; Hinz B
Drug Saf; 2004; 27(13):1059-67. PubMed ID: 15471510
[TBL] [Abstract][Full Text] [Related]
16. Access to new medicines in New Zealand compared to Australia.
Wonder M; Milne R
N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
[TBL] [Abstract][Full Text] [Related]
17. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
Conroy S
Acta Paediatr; 2003 Apr; 92(4):408-10. PubMed ID: 12801103
[TBL] [Abstract][Full Text] [Related]
18. Lack of drug preparations for use in children in Brazil.
Costa PQ; Rey LC; Coelho HL
J Pediatr (Rio J); 2009; 85(3):229-35. PubMed ID: 19452078
[TBL] [Abstract][Full Text] [Related]
19. Off-label and unlicensed medicines to hospitalised children in Norway.
Teigen A; Wang S; Truong BT; Bjerknes K
J Pharm Pharmacol; 2017 Apr; 69(4):432-438. PubMed ID: 27334565
[TBL] [Abstract][Full Text] [Related]
20. Paediatric formulations--getting to the heart of the problem.
Standing JF; Tuleu C
Int J Pharm; 2005 Aug; 300(1-2):56-66. PubMed ID: 15979830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
